Anticonvulsants

Point-of-Sale (POS) edits are safety limitations that are automatically verified through computer programming at the time that a prescription claim is submitted at the pharmacy. These edits can be applied to *any* medication, whether or not it is listed in the Preferred Drug List / Non-Preferred Drug List (PDL/NPDL). The first section of this document is organized to follow the order of the therapeutic classes in the PDL/NPDL and explains the POS edits for those medications.

POS Abbreviations

AL – Age Limit	DD – Drug-Drug Interaction	MD – Maximum Dose Limit	TD - Therapeutic Duplication
BH – Behavioral Health Clinical Authorization for Children Younger than 7 Years of Age	DS – Maximum Days' Supply Allowed	PR – Enrollment in a Physician- Supervised Program Required	UN – Drug Use Not Warranted
BY – Diagnosis Codes Bypass Some Requirements	DT – Duration of Therapy Limit	PU – Prior Use of Other Medication is Required	X – Prescriber Must Have 'X' DEA Number
CL – Additional Clinical Information is Required	DX – Diagnosis Code Requirement	QL – Quantity Limit	YQ – Yearly Quantity Limit
CU – Concurrent Use with Other Medication is Restricted	ER – Early Refill	RX – Specific Prescription Requirement	

Pharmacy Prior Authorization Phone Numbers for MCOs and FFS

Aetna Better Health of Louisiana 1-855-242-0802
AmeriHealth Caritas Louisiana 1-800-684-5502
Fee-for-Service (FFS) Louisiana Legacy Medicaid 1-866-730-4357
Healthy Blue 1-844-521-6942
Louisiana Healthcare Connections 1-888-929-3790
UnitedHealthcare 1-800-310-6826

Anticonvulsants

POS Edits

AL – Fycompa® (perampanel) is limited to use in recipients who are at least 4 years old. The age limit may be overridden at the pharmacy POS after the dispensing pharmacist consults with the prescriber to verify necessity of prescribing perampanel for a child younger than 4 years of age.

BH – Additional behavioral-health related clinical information (trial of behavioral therapy, etc.) is required for carbamazepine (<u>Equetro®</u>) and clonazepam when requested for a behavioral health diagnosis for recipients who are younger than 7 years of age.

BY – Pharmacy claims for selected anxiolytics, when submitted with a seizure-related diagnosis code will bypass the behavioral-health clinical authorization requirement, the restriction on concurrent use with opioids, and quantity limits. Bypass diagnosis codes can be found at THIS LINK. (see Anticonvulsant Quantity Limits with Bypass Diagnosis Codes chart below).

CU – Benzodiazepines are monitored at POS for concurrent use with opioids and buprenorphine-containing products.

- Concurrent pharmacy claims for benzodiazepines and buprenorphine will deny.
- Incoming benzodiazepine pharmacy claims will deny when the recipient has an active prescription (a prescription in which the days' supply has not expired) for an opioid.

MD – Selected agents have a	Generic (Brand Example)	Maximum Daily Dose
maximum daily dose as listed in the	Clobazam (Onfi®, Sympazan®)	40mg per day
chart to the right.	Eslicarbazepine (Aptiom®)	<u>1600mg per day</u>

PU – For Epidiolex®, the pharmacy POS system verifies that there has been a paid claim in the previous 365 days for **AT LEAST TWO** of the following agents [brand/generic or preferred/non-preferred]:

- Clobazam
- Felbamate
- Lamotrigine
- Levetiracetam
- Rufinamide
- Topiramate
- Valproate derivatives

-	Quantity Limits		
QL – Selected agents have quantity limits as listed in the chart to the right.	Generic (Brand Example)	Quantity Limit	
	Clonazepam (Klonopin®)	90 units <u>perin</u> 30 days	
	Midazolam (Nayzilam®)	5 boxes (10 doses) per 30 days	

TD – Clonazepam is monitored at the pharmacy POS for duplication of therapy with other benzodiazepines, and with oxybate (Xyrem®), and with oxybate salts (XywayTM).

Revision / Date	Implementation Date
Created POS Document	November 2020
Added previous-use requirement for Epidiolex® / December 2020	April 2021
Added maximum daily dose for Onfi® and Aptiom®, added quantity limit for Nayzilam®, formatting changes / January 2022	July 2022